ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
Berlin, Germany and Zurich, Switzerland – April 12, 2023 ProBioGen, the Berlin-based CDMO and technology provider, reported today that revenues for the fiscal year 2022 (FY22)..
ProBioGen Delivers Strong 2022 Performance, Investing for Growth in 2023
Berlin, Germany – March 30, 2023 ProBioGen, the Berlin-based CDMO and technology provider, reported today that revenues for the fiscal year 2022 (FY22) grew 35% vs FY21. In a year..
ProBioGen’s Growth Strategy Continues Successfully
Julian Collins, Jana Windt and Michiel Stork Join Biopharma Company’s Leadership Team Berlin, Germany – March 2, 2023 ProBioGen has seen significant growth with over 300 employees..
Another Clinical Asset Using ProBioGen's GlymaxX® Technology Begins Phase III
Berlin, Germany – January 26, 2023 ProBioGen today announced that a Novartis clinical candidate using its antibody-dependent cellular cytotoxicity (ADCC) technology, GlymaxX, has..
ProBioGen’s Vaccine Production Cell Line AGE1.CR.pIX® Used for Clinical Production
Berlin, Germany – January 18, 2023 ProBioGen is announcing another important clinical milestone for its proprietary viral vector and vaccine production cell line AGE1.CRpIX®. Our..
ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck® Transposase Technology
Berlin, Germany – January 10, 2023 ProBioGen announced today a new non-exclusive collaboration with Boehringer Ingelheim on ProBioGen's DirectedLuck® transposase technology...
ProBioGen Co-Develops New Freedom™ ExpiCHO-S™ Cell Line Development Kit
Berlin, Germany – October 27, 2022 Following the success of the Gibco™ Freedom™ CHO-S Cell Line Development Kit, ProBioGen and Thermo Fisher Scientific have teamed up again to..
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Mar 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
May 29, 2024
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Mar 27, 2024
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Mar 13, 2024
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
Sep 26, 2023
